Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy.

Schumann K, Klespe KC, Mauch C, Loquai C, Schultheis U, Börger S, Thiem A, Emmert S, Hoellwerth M, Kölblinger P, Nguyen VA, Wanner M, Richtig E, Peitsch WK, Harth W, Zenderowski V, Braun AD, Mengoni M, Dummer R, Mangana J, Maul LV, Meiß F, Rappersberger K, Persa OD, Biedermann T, Posch C

Open source

DOI: 10.1111/jdv.20708
Published: 2025 Nov
Container: Journal of the European Academy of Dermatology and Venereology : JEADV
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/jdv.20708,
  title = {Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy.},
  author = {Schumann K and Klespe KC and Mauch C and Loquai C and Schultheis U and Börger S and Thiem A and Emmert S and Hoellwerth M and Kölblinger P and Nguyen VA and Wanner M and Richtig E and Peitsch WK and Harth W and Zenderowski V and Braun AD and Mengoni M and Dummer R and Mangana J and Maul LV and Meiß F and Rappersberger K and Persa OD and Biedermann T and Posch C},
  year = {2025},
  journal = {Journal of the European Academy of Dermatology and Venereology : JEADV},
  doi = {10.1111/jdv.20708},
  url = {https://doi.org/10.1111/jdv.20708}
}

RIS

TY  - JOUR
TI  - Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy.
AU  - Schumann K
AU  - Klespe KC
AU  - Mauch C
AU  - Loquai C
AU  - Schultheis U
AU  - Börger S
AU  - Thiem A
AU  - Emmert S
AU  - Hoellwerth M
AU  - Kölblinger P
AU  - Nguyen VA
AU  - Wanner M
AU  - Richtig E
AU  - Peitsch WK
AU  - Harth W
AU  - Zenderowski V
AU  - Braun AD
AU  - Mengoni M
AU  - Dummer R
AU  - Mangana J
AU  - Maul LV
AU  - Meiß F
AU  - Rappersberger K
AU  - Persa OD
AU  - Biedermann T
AU  - Posch C
PY  - 2025
JO  - Journal of the European Academy of Dermatology and Venereology : JEADV
DO  - 10.1111/jdv.20708
UR  - https://doi.org/10.1111/jdv.20708
ER  -

APA

K, S., KC, K., C, M., C, L., U, S., S, B., A, T., S, E., M, H., P, K., VA, N., M, W., E, R., WK, P., W, H., V, Z., AD, B., M, M., R, D., J, M., LV, M., F, M., K, R., OD, P., T, B., & C, P. (2025). Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy.. Journal of the European Academy of Dermatology and Venereology : JEADV. https://doi.org/10.1111/jdv.20708

Source records

pubmed · retrieved 2026-09-26T16:51:40.807Z